Co-discoverer of reverse transcriptase at 32, Nobel Prize at 37, played a key role at the 1975 Asilomar comference.

Carlo Acutis will likely be the first saint with Pokémon mentioned in his bio; I'd like to think he'd share my enthusiasm for Quaxly. Beyond the hype of being a patron saint of gamers, however, I find it more compelling that he lived in our context and reminds us of God's presence in all things. 1/2

Results of a pilot study led by investigators at @mskcancercenter.bsky.social showed that interleukin-18 “armored” CAR T cells targeting CD371 were effective at treating relapsed/refractory acute myeloid #leukemia at low doses. @markgeyermd.bsky.social Learn more: bit.ly/4mFwo9q

The bells of St. Patrick’s ring out in joy!! As the Church welcomes our new Holy Father, the Cathedral—America’s parish—joins Catholics around the world in celebration and prayer. Let us give thanks for the gift of our new pope. Habemus Papam. #NewPope #StPatricksCathedral #CatholicChurch #NY

Robert Francis Prevost will be the next pope and has taken the name Leo XIV. An American Pope. I hope he promotes unconditional love and service, especially towards the poor and marginalized. Let's pray.

Congratulations to @mark-carney.bsky.social for leading his party to victory tonight, and for his message of hope and unity for his country His recall of the selfless acts of Gander (Newfoundland) following 9/11 reflects the very best of the Canadian spirit.

#BREAKING: Mark Carney and the Liberal party will form government www.thestar.com/politics/fed...

Pope Francis lifted the world as he led the Church with his profound moral voice. As he returns to God, may his call to humility and concern for the least among us continue to resound.

Pope Francis died at 88, the Vatican announced Monday, ending a pontificate that sought to reshape the Roman Catholic Church into a more inclusive institution. Cardinals will now decide whether to continue his approach or restore more doctrinaire leadership. Follow live updates: nyti.ms/42RZB9n

Luke 23:41-43 RSV And we indeed justly; for we are receiving the due reward of our deeds; but this man has done nothing wrong.” And he said, “Jesus, remember me when you come into your kingdom.” And he said to him, “Truly, I say to you, today you will be with me in Paradise.”

I said my main goal of this trip was to meet with Kilmar. Tonight I had that chance. I have called his wife, Jennifer, to pass along his message of love. I look forward to providing a full update upon my return.

An ostensibly conservative administration drawing this much condemnation from Judge Wilkinson is truly a sign of the dangerous times in which we find ourselves.

Many products sold in the U.S. are made in El Salvador. In response to the El Salvador president’s statements today, we’re calling for an immediate boycott of all Salvadoran-made goods. Please help by listing any products or brands made in El Salvador in the comments below.

I have been critical of some of the actions of @harvard.edu in recent years, but am proud to be an alumnus of the College tonight. Time to make a donation. Illegitimum non carborundum; Domine salvum fac.

A disgraceful day.

@drkomanduri.bsky.social receives @astct.bsky.social Advocacy Award. Can we replicate his passion?

Feel free to listen to my chat with Dr. Jabbour on BCR::ABL+/Philadelphia chromosome-positive ALL, including ponatinib and novel therapeutic approaches!

MVP

I believe that most of our society values science and scientists. We need to continue to communicate our findings and value to the public and advocate for increased research funding, especially for young investigators->they are the future.

Pains me to root for Philadelphia as a NE Patriots fan, but happy for the Eagles and Jalen Hurts!

For Maths fans, 2025 is a square. 45² = 45 x 45 = 2025 Also, 9² x 5² = 2025 40² + 20² + 5² = 2025 My favourite? 1³+2³+3³+4³+5³+6³+7³+8³+9³ = 2025 #Mathematics #teaching #education

A lot of people seem to struggle with this but 50% is actually much better than 0%

"Blessed are the peacemakers, for they will be called children of God." Matthew 5:9

Caleb making a miraculous throw while the crowd chants "sell the team" right after another timeout issue. Your 2024 Chicago Bears.

This is excellent news and an early Christmas/Hanukkah gift, despite this agreement only being reached at the 11th hour and causing considerable stress for patients, families, and caregivers.

Time to see where those interested in hematology engaged online during #ASH24... Thousands of posts were published on #Bluesky while Twitter / X still see massive levels of congress engagement online #MedTwitter #MedSky @majorajay.bsky.social @markgeyermd.bsky.social @hemedoc.bsky.social

This is your last chance to see incredible research at the #ASH24 poster session today! Don't miss posters by Drs. Gunjan Shah, Carlyn Rose Tan, & Pallawi Torka. @mskcancercenter.bsky.social @szusmani.bsky.social 6-8 p.m. PST https://buff.ly/3ZLbSey https://buff.ly/3OOjjeG https://buff.ly/3Vum0Wv

Dr. Ibrahim Aldoss from @cityofhope.bsky.social presents data on definitive CD19-targeted CAR T-cell therapy in pts ≥55 years w/ B-cell ALL in CR1. Lower disease burden pre-conditioning/LDC associated w/ ↓ toxicity and ↑ LFS. Pilot study schema as below. #ash24 #allsm 1/x

Susana Rives from Hospital Sant Joan de Déu (Barecelona) presents on 2nd CAR T-cell infusion (CART2), CD19 or CD22 targeted, auto or allo, in pts w/ R/R B-ALL using a multicenter registry. 41/345 pts underwent CART2 post-CART1. 1/x #ash24 #allsm

Dr. Jing Pan from Beijing Gobroad Hospital presents update on outcomes post-donor derived CD7 CAR T-cell therapy for pts w/ R/R T-ALL/LBL. Risks of relapse and death from infection significant in prior studies; authors aimed to clarify predictors of survival in 75 pts. 1/x #ash24 #allsm

Dr. Jabbour from @mdanderson.bsky.social presents on long-term outcomes following obecabtagene autoleucel (obe-cel, Aucatzyl) stratified by depth of response by clonoSEQ NGS (sensitivity 10^-6). 84% of responders achieved clonoSEQ negativity. 1/x #ash24 #allsm

Dr. Anna Torrent presents data from Spanish PETHEMA LAL19 trial (schema below) comparing chemotherapy vs alloHCT in 452 pts (median age 30) based on b/l genetic risk and MRD levels by FACS at EOI and EOC. 1/x #ASH24 #allsm

Dr. Nicola Goekbuget from Goethe University, University Hospital, Frankfurt reports on results of GMALL 08/2013 (age 18-55); this included randomization for Ph-neg HR ALL pts w/ available donor and molecular CR (<0.01% by qPCR) after induction phase 2 (IP2). 1/x #ash24 #allsm

Dr. Heike Pfeifer presents on GMALL Trial 08/2013 (imatinib + reduced-intensity chemo -> alloHCT regardless of MRD) in pts 18-55 w/ ND BCR::ABL+ ALL. 174 pts, median age 42. Rates of MRD response improved w/ time. #ash24 #allsm 1/x

Jieping Lin from Southern Medical University, Guangzhou, China presents on the HDAC inhibitor (HDACi) tucidinostat + pediatric-inspired chemo in pts age 14-55 w/ ETP-ALL/LBL. Role of HDACi hypothesized based on recurrent mutations in histone-modifying genes. 1/x #allsm #ash24

Dr. Michela Ansuinelli from Sapienza University of Rome reports on immunomodulatory effect of DAS + BLIN vs PON + BLIN in ND BCR::ABL+ ALL. Previous reports: DAS + BLIN ↑ NK, T-NK and CD8+ T cells, and a ↓of (Tregs), more evident after repeated cycles of BLIN. 1/x #allsm #ash24

Dr. Short from @mdanderson.bsky.social presents an update on their ponatinib/blinatumomab (pon/blin) experience. Regimen updated to include 15 LPs (rather than 12) to protect against CNS relapse. Pts w/ persistent BCR::ABL were clonoSEQ neg, suggesting BCR::ABL wasn't MRD. 1/x #ash24 #allsm

Dr. Shanshan Suo presents on venetoclax + HAG (homoharringtonine [aka HHT or omacetaxine] + ARA-C + G-CSF) for pts w/ ETP-ALL. Authors believe HHT synergizes w/ ven in ETP-ALL in vivo and in vitro. 31 txed pts received V-HAG (ven d1-14, longer if blasts ≥5% d14, HHT d1-10, LDAC d1-14, G-CSF d1-14).

Dr. Sabina Chiaretti from Sapienza University of Rome presents on GIMEMA ALL2820 trial for adults w. BCR::ABL+ ALL; key changes from D-ALBA included ponatinib (not dasatinib) as TKI, ↑ CNS ppx, and allocation to alloHCT based on MRD+ or BCR::ABL+ with adverse genetic features. 1/x #allsm #ash24

Dr. Dan DeAngelo from @danafarber.bsky.social presents on dose optimization of inotuzumab (InO) in adults w/ R/R B-ALL. Post-marketing study done to investigate 1.2 vs 1.8 mg/m2/cycle w/ 1° endpoints of CR/CRi and VOD/SOS rates (RCT design after run-in phase as below). 1/x #ash24 #allsm